{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:52Z","timestamp":1791225892391,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical need for safe and effective vaccines to ensure fair and equitable supply for all countries. Here, we report on the development of a highly efficacious mRNA vaccine, SW0123 that is composed of sequence-modified mRNA encoding the full-length SARS-CoV-2 Spike protein packaged in core\u2013shell structured lipopolyplex (LPP) nanoparticles. SW0123 is easy to produce using a large-scale microfluidics-based apparatus. The unique core\u2013shell structured nanoparticle facilitates vaccine uptake and demonstrates a high colloidal stability, and a desirable biodistribution pattern with low liver targeting effect upon intramuscular administration. Extensive evaluations in mice and nonhuman primates revealed strong immunogenicity of SW0123, represented by induction of Th1-polarized T cell responses and high levels of antibodies that were capable of neutralizing not only the wild-type SARS-CoV-2, but also a panel of variants including D614G and N501Y variants. In addition, SW0123 conferred effective protection in both mice and non-human primates upon SARS-CoV-2 challenge. Taken together, SW0123 is a promising vaccine candidate that holds prospects for further evaluation in humans.<\/jats:p>","DOI":"10.1038\/s41392-021-00634-z","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:03:05Z","timestamp":1622422985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8134-4010","authenticated-orcid":false,"given":"Ren","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-1576","authenticated-orcid":false,"given":"Ang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhan","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-5589","authenticated-orcid":false,"given":"Jincun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-0247","authenticated-orcid":false,"given":"Xiaozhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"634_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"Le,T Thanh","year":"2020","unstructured":"Thanh, Le,T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305\u2013306 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"634_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"634_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"634_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713\u2013721 (2020).","journal-title":"Cell"},{"key":"634_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"634_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"634_CR9","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N. Engl. J. Med. 383, e74 (2020).","journal-title":"N. Engl. J. Med."},{"key":"634_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 (2020).","journal-title":"Cell"},{"key":"634_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 (2020).","journal-title":"Cell"},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.cell.2020.05.041","volume":"181","author":"GD Sempowski","year":"2020","unstructured":"Sempowski, G. D. et al. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell 181, 1458\u20131463 (2020).","journal-title":"Cell"},{"key":"634_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"634_CR14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"SE Oliver","year":"2020","unstructured":"Oliver, S. E. et al. The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for use of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 2020. Morb. Mortal. Wkly Rep. 69, 1922\u20131924 (2020).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"634_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fimmu.2013.00354","volume":"4","author":"S Flingai","year":"2013","unstructured":"Flingai, S. et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front. Immunol. 4, 354 (2013).","journal-title":"Front. Immunol."},{"key":"634_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1\u201311 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"634_CR17","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1021\/mp500367k","volume":"11","author":"ME Gindy","year":"2014","unstructured":"Gindy, M. E. et al. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics. Mol. Pharm. 11, 4143\u20134153 (2014).","journal-title":"Mol. Pharm."},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang, N. N. et al. A Thermostable mRNA Vaccine against COVID-19. Cell 182, 1271\u20131283 (2020).","journal-title":"Cell"},{"key":"634_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 169, 176 (2017).","journal-title":"Cell"},{"key":"634_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).","journal-title":"Nat. Commun."},{"key":"634_CR21","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055."},{"key":"634_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15585\/mmwr.mm7003e2","volume":"70","author":"SE Galloway","year":"2021","unstructured":"Galloway, S. E. et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. Morb. Mortal. Wkly Rep. 70, 95\u201399 (2021).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"634_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345\u2013351 (2015).","journal-title":"J. Control Release"},{"key":"634_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med"},{"key":"634_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat Immunol."},{"key":"634_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971\u2013977 (2020).","journal-title":"Immunity"},{"key":"634_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 Disease and unexposed individuals. Cell 181, 1489\u20131501 (2020).","journal-title":"Cell"},{"key":"634_CR28","first-page":"313","volume":"18","author":"T Rivera-Hernandez","year":"2014","unstructured":"Rivera-Hernandez, T. et al. The contribution of non-human primate models to the development of human vaccines. Discov. Med. 18, 313\u2013322 (2014).","journal-title":"Discov. Med."},{"key":"634_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1126\/science.abb7314","volume":"368","author":"B Rockx","year":"2020","unstructured":"Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012\u20131015 (2020).","journal-title":"Science"},{"key":"634_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herve","year":"2019","unstructured":"Herve, C. et al. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines 4, 39 (2019).","journal-title":"NPJ Vaccines"},{"key":"634_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","volume":"125","author":"S Persano","year":"2017","unstructured":"Persano, S. et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials 125, 81\u201389 (2017).","journal-title":"Biomaterials"},{"key":"634_CR32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.cell.2020.10.004","volume":"183","author":"AK Banerjee","year":"2020","unstructured":"Banerjee, A. K. et al. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183, 1325\u20131339 (2020).","journal-title":"Cell"},{"key":"634_CR33","doi-asserted-by":"crossref","unstructured":"Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 383, 2439\u20132450 (2020).","DOI":"10.1056\/NEJMoa2027906"},{"key":"634_CR34","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 35, 109017 (2021).","DOI":"10.1016\/j.celrep.2021.109017"},{"key":"634_CR35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","volume":"184","author":"EC Thomson","year":"2021","unstructured":"Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171\u20131187 (2021).","journal-title":"Cell"},{"key":"634_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"key":"634_CR37","doi-asserted-by":"publisher","first-page":"20140236","DOI":"10.1098\/rstb.2014.0236","volume":"370","author":"AM Collins","year":"2015","unstructured":"Collins, A. M. et al. The mouse antibody heavy chain repertoire is germline-focused and highly variable between inbred strains. Philos. Trans. R Soc. Lond. B 370, 20140236 (2015).","journal-title":"Philos. Trans. R Soc. Lond. B"},{"key":"634_CR38","doi-asserted-by":"publisher","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"634_CR39","doi-asserted-by":"publisher","first-page":"e1006565","DOI":"10.1371\/journal.ppat.1006565","volume":"13","author":"KV Houser","year":"2017","unstructured":"Houser, K. V. et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 13, e1006565 (2017).","journal-title":"PLoS Pathog."},{"key":"634_CR40","doi-asserted-by":"publisher","first-page":"eabd6832","DOI":"10.1126\/sciimmunol.abd6832","volume":"5","author":"C Maucourant","year":"2020","unstructured":"Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 5, eabd6832 (2020).","journal-title":"Sci Immunol."},{"key":"634_CR41","doi-asserted-by":"publisher","first-page":"e144734","DOI":"10.1172\/JCI144734","volume":"131","author":"S Falck-Jones","year":"2021","unstructured":"Falck-Jones, S. et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J Clin Invest. 131, e144734 (2021).","journal-title":"J Clin Invest"},{"key":"634_CR42","doi-asserted-by":"publisher","first-page":"eabe8063","DOI":"10.1126\/sciimmunol.abe8063","volume":"5","author":"AC Karlsson","year":"2020","unstructured":"Karlsson, A. C., Humbert, M. & Buggert, M. The known unknowns of T cell immunity to COVID-19. Sci Immunol. 5, eabe8063 (2020).","journal-title":"Sci Immunol."},{"key":"634_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168 (2020).","journal-title":"Cell"},{"key":"634_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bsheal.2020.08.004","volume":"2","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf. Health 2, 226\u2013231 (2020).","journal-title":"Biosaf. Health"},{"key":"634_CR45","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cell.2020.06.040","volume":"182","author":"ND Grubaugh","year":"2020","unstructured":"Grubaugh, N. D., Hanage, W. P. & Rasmussen, A. L. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell 182, 794\u2013795 (2020).","journal-title":"Cell"},{"key":"634_CR46","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1172\/JCI135020","volume":"130","author":"A Lin","year":"2020","unstructured":"Lin, A. et al. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. J. Clin. Invest. 130, 2332\u20132346 (2020).","journal-title":"J. Clin. Invest."},{"key":"634_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41392-020-00269-6","volume":"5","author":"S Lu","year":"2020","unstructured":"Lu, S. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct. Target Ther. 5, 157 (2020).","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00634-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T09:24:05Z","timestamp":1669800245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00634-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1038\/s41392-021-00634-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stemirna Therapeutics filed patents on patent application entitled \u201cA prophylactic or therapeutical 2019-nCoV mRNA vaccine\u201d. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}